• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从护士管理者视角看爱尔兰监狱中的丙型肝炎病毒筛查与治疗——一项质性探索

Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration.

作者信息

Crowley D, Van Hout M C, Murphy C, Kelly E, Lambert J S, Cullen W

机构信息

Irish College of General Practitioners, Lincoln Place, Dublin, Ireland.

Public Health Institute, Liverpool John Moore's University, Liverpool, UK.

出版信息

BMC Nurs. 2019 Jun 13;18:23. doi: 10.1186/s12912-019-0347-x. eCollection 2019.

DOI:10.1186/s12912-019-0347-x
PMID:31210751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6567378/
Abstract

BACKGROUND

Prisoners carry a greater burden of physical, communicable and psychiatric disease compared to the general population. Prison health care structures are complex and provide challenges and opportunities to engage a marginalised and poorly served group with health care including Hepatitis C Virus (HCV) screening, assessment and treatment. Optimising HCV management in prisons is a public health priority. Nurses are the primary healthcare providers in most prisons globally. Understanding the barriers and facilitators to prisoners engaging in HCV care from the perspectives of nurses is the first step in implementing effective strategies to eliminate HCV from prison settings. The aim of this study was to identify the barriers and facilitators to HCV screening and treatment in Irish prisons from a nurse perspective and inform the implementation of a national prison-based HCV screening program.

METHODS

A qualitative study using focus group methodology underpinned by grounded theory for analysis in a national group of nurse managers ( = 12).

RESULTS

The following themes emerged from the analysis; security and safety requirements impacting patient access, staffing and rostering issues, prison nurses' skill set and concerns around phlebotomy, conflict between maintaining confidentiality and concerns for personal safety, peer workers, prisoners' lack of knowledge, fear of treatment and stigma, inter-prison variations in prisoner health needs and health service delivery and priority, linkage to care, timing of screening and stability of prison life.

CONCLUSIONS

Prison nurses are uniquely placed to identify barriers and facilitators to HCV screening and treatment in prisoners and inform changes to health care practice and policy that will optimi the public health opportunity that incarceration provides.

摘要

背景

与普通人群相比,囚犯承受着更大的身体、传染病和精神疾病负担。监狱医疗保健结构复杂,为使边缘化且医疗服务不足的群体获得包括丙型肝炎病毒(HCV)筛查、评估和治疗在内的医疗保健带来了挑战和机遇。优化监狱中的HCV管理是一项公共卫生优先事项。在全球大多数监狱中,护士是主要的医疗服务提供者。从护士的角度了解囚犯接受HCV护理的障碍和促进因素,是在监狱环境中实施有效策略以消除HCV的第一步。本研究的目的是从护士的角度确定爱尔兰监狱中HCV筛查和治疗的障碍和促进因素,并为实施全国性的基于监狱的HCV筛查计划提供依据。

方法

采用焦点小组方法进行定性研究,并以扎根理论为基础进行分析,研究对象为一组全国性的护士管理人员(n = 12)。

结果

分析得出以下主题;安全要求影响患者就医,人员配备和排班问题,监狱护士的技能组合以及对静脉穿刺的担忧,保密与个人安全担忧之间的冲突,同伴工作人员,囚犯知识匮乏,对治疗的恐惧和耻辱感,监狱间囚犯健康需求和医疗服务提供及优先级的差异,与护理的联系,筛查时间和监狱生活的稳定性。

结论

监狱护士处于独特地位,能够识别囚犯HCV筛查和治疗的障碍和促进因素,并为优化监禁所提供的公共卫生机会的医疗保健实践和政策变革提供依据。

相似文献

1
Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration.从护士管理者视角看爱尔兰监狱中的丙型肝炎病毒筛查与治疗——一项质性探索
BMC Nurs. 2019 Jun 13;18:23. doi: 10.1186/s12912-019-0347-x. eCollection 2019.
2
Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration.从监狱长和狱警视角看爱尔兰监狱中的丙型肝炎病毒筛查与治疗——一项定性探索
Health Justice. 2018 Dec 19;6(1):23. doi: 10.1186/s40352-018-0081-6.
3
Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.阻碍和促进丙型肝炎(HCV)筛查和治疗的因素——囚犯视角的描述。
Harm Reduct J. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z.
4
Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care.竞争的优先级和第二次机会——对囚犯通过丙型肝炎连续护理过程的定性探索。
PLoS One. 2019 Sep 11;14(9):e0222186. doi: 10.1371/journal.pone.0222186. eCollection 2019.
5
Development of an evidence-based hepatitis C education program to enhance public health literacy in the Australian prison sector: The Hepatitis in Prisons Education program (HepPEd).开发基于证据的丙型肝炎教育计划,以提高澳大利亚监狱部门的公众健康素养:监狱中的肝炎教育计划(HepPEd)。
Int J Drug Policy. 2024 Jul;129:104461. doi: 10.1016/j.drugpo.2024.104461. Epub 2024 Jul 5.
6
Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.向囚犯提供 HCV 治疗是一个重要的机会:基于欧洲政策和实践评估的关键原则。
BMC Public Health. 2019 Jan 8;19(1):30. doi: 10.1186/s12889-018-6357-x.
7
Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners.评估同伴支持性筛查作为囚犯丙型肝炎病例发现模式。
Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
8
Hepatitis C virus infection in Irish drug users and prisoners - a scoping review.爱尔兰吸毒者和囚犯中的丙型肝炎病毒感染 - 范围综述。
BMC Infect Dis. 2019 Aug 8;19(1):702. doi: 10.1186/s12879-019-4218-6.
9
Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).考虑在澳大利亚监狱扩大治疗即预防措施:澳大利亚“监测和治疗丙型肝炎囚犯”项目(SToP-C)专家利益相关者的定性子研究。
Harm Reduct J. 2021 Apr 26;18(1):46. doi: 10.1186/s12954-021-00494-4.
10
Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.了解监狱中丙型肝炎病毒感染直接作用抗病毒治疗的促进因素和障碍。
J Viral Hepat. 2018 Dec;25(12):1526-1532. doi: 10.1111/jvh.12987. Epub 2018 Sep 19.

引用本文的文献

1
A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons.监狱中乙肝和丙肝防治项目障碍与促进因素的定性系统评价
J Viral Hepat. 2025 Feb;32(2):e14049. doi: 10.1111/jvh.14049.

本文引用的文献

1
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218].《欧洲肝脏研究学会丙型肝炎治疗推荐:系列最终更新版》勘误 [《肝脏病学杂志》73卷(2020年)1170 - 1218页]
J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1.
2
Pangenotypic regimens and the next generation hepatitis C virus therapy.泛基因型治疗方案与下一代丙型肝炎病毒疗法
Clin Liver Dis (Hoboken). 2017 Jun 29;9(6):131-133. doi: 10.1002/cld.635. eCollection 2017 Jun.
3
Treatment of HCV in persons who inject drugs: Treatment as prevention.对注射毒品者的丙型肝炎治疗:治疗即预防。
Clin Liver Dis (Hoboken). 2017 Apr 20;9(4):77-80. doi: 10.1002/cld.626. eCollection 2017 Apr.
4
Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration.从监狱长和狱警视角看爱尔兰监狱中的丙型肝炎病毒筛查与治疗——一项定性探索
Health Justice. 2018 Dec 19;6(1):23. doi: 10.1186/s40352-018-0081-6.
5
Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.阻碍和促进丙型肝炎(HCV)筛查和治疗的因素——囚犯视角的描述。
Harm Reduct J. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z.
6
Incidence of hepatitis C among people who inject drugs in Ireland.爱尔兰注射毒品者中丙型肝炎的发病率。
Hepatol Med Policy. 2017 Jan 26;2:7. doi: 10.1186/s41124-017-0024-1. eCollection 2017.
7
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.8 周和 12 周 glecaprevir/pibrentasvir 治疗的高 SVR12:无肝硬化的 HCV 基因型 1-6 患者的综合分析。
J Hepatol. 2018 Aug;69(2):293-300. doi: 10.1016/j.jhep.2018.03.007. Epub 2018 Mar 16.
8
Prison Health Care Governance: Guaranteeing Clinical Independence.监狱医疗保健治理:保障临床独立性。
Am J Public Health. 2018 Apr;108(4):472-476. doi: 10.2105/AJPH.2017.304248. Epub 2018 Feb 22.
9
Telementoring with project ECHO: a pilot study in Europe.通过项目ECHO进行远程指导:欧洲的一项试点研究。
BMJ Innov. 2017 Jul;3(3):144-151. doi: 10.1136/bmjinnov-2016-000141. Epub 2017 Aug 24.
10
Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol.《Hepcare Europe - 填补丙型肝炎治疗空白:研究方案》。
Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):303-314. doi: 10.1080/17474124.2018.1424541. Epub 2018 Jan 16.